EUVIMEDEUVIMED entdecken
Kontrollierte klinische StudieOpen Access

Influence of CYP2A6 Genetic Variation, Nicotine Dependence Severity, and Treatment on Smoking Cessation Success

Meghan J Chenoweth, Caryn Lerman iD, Jo Knight iD, Rachel F Tyndale iD

Nicotine and Tobacco Research · 2023

DOI: 10.1093/ntr/ntac268 ↗

Kurz gefasst

Kontrollierte klinische Studie in der Zeitschrift Nicotine and Tobacco Research, 2023. Verfasst von Meghan J Chenoweth und 3 weiteren Autor:innen. Beteiligte Einrichtung: Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Smoking Cessation, Tobacco Use Disorder. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, Canadian Institutes of Health Research, CIHR Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Genetic variation in Cytochrome P450 2A6 (CYP2A6), the major nicotine metabolizing enzyme, is associated with nicotine dependence and smoking cessation. Nicotine dependence severity also predicts smoking cessation. Our goals were to determine how CYP2A6 variation and nicotine dependence alter smoking cessation, and whether dependence could refine CYP2A6-based treatment recommendations. Aims and Methods Adult smokers treated for 12 weeks with placebo, nicotine patch, or varenicline (NCT01314001) were grouped as CYP2A6 normal (n = 567) or slow (n = 432) nicotine metabolizers based on a CYP2A6 weighted genetic risk score. Fagerström test for nicotine dependence scores were measured at baseline and biochemically verified smoking cessation was assessed at end of treatment.

Results

Dependence neither mediated nor moderated an association between CYP2A6 variation and smoking cessation overall, within any treatment arm, or after stratifying by ancestry (n = 591 European, n = 408 African ancestry) or sex (n = 444 women, n = 555 men). In within-treatment analyses, the mediation effect odds ratio (OR) ranged from 0.95 to 1.00 and the bias-corrected 95% confidence interval contained 1. Moderation (i.e. interaction) effect ORs ranged from 0.88 to 1.61 (p = .397–.828). For CYP2A6 normal metabolizers, quit rates on varenicline were similar for those with high (41.1%) and low (43.4%) dependence, while quit rates were lower for those with high versus low dependence on both patch (16.5 vs. 29.7%) and placebo (8.9 vs. 18.5%). CYP2A6 slow metabolizers with high versus low dependence had lower quit rates in all three treatment arms.

Conclusions

Although nicotine dependence severity neither mediated nor moderated CYP2A6 associations with smoking cessation, incorporating information on dependence may optimize the choice of smoking cessation treatment aid in CYP2A6 normal and slow metabolizers.

Implications

Variation in CYP2A6 and nicotine dependence severity alter smoking cessation success. Our findings suggest that while nicotine dependence severity is unlikely to mediate or moderate CYP2A6 associations with cessation, incorporating patient information on both CYP2A6 and nicotine dependence severity may lead to improved smoking cessation strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Smoking CessationTobacco Use DisorderAdultFemaleHumansMaleCytochrome P-450 CYP2A6Genetic VariationNicotineVarenicline

Substanzen

CYP2A6 protein, humanCytochrome P-450 CYP2A6NicotineVarenicline

Autor:innen und Institutionen

  • Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
  • Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
  • Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Department of Psychiatry and USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
  • Data Science Institute, Lancaster University Medical School, Lancaster, UK.

ORCID-Profile: Caryn Lerman, Jo Knight, Rachel F Tyndale

Förderung

  • NIDA NIH HHS
  • Canadian Institutes of Health Research
  • CIHR Foundation
  • National Institutes of Health
  • Centre for Addiction and Mental Health
  • Campbell Family Mental Health Research Institute

Zitieren

APA

Chenoweth, M. J., Lerman, C., Knight, J., & Tyndale, R. F. (2023). Influence of CYP2A6 Genetic Variation, Nicotine Dependence Severity, and Treatment on Smoking Cessation Success. Nicotine and Tobacco Research. https://doi.org/10.1093/ntr/ntac268

Vancouver

Chenoweth MJ, Lerman C, Knight J, Tyndale RF. Influence of CYP2A6 Genetic Variation, Nicotine Dependence Severity, and Treatment on Smoking Cessation Success. Nicotine and Tobacco Research. 2023. doi:10.1093/ntr/ntac268

BibTeX
@article{Chenoweth2023,
  author = {Chenoweth, Meghan J and Lerman, Caryn and Knight, Jo and Tyndale, Rachel F},
  title = {Influence of CYP2A6 Genetic Variation, Nicotine Dependence Severity, and Treatment on Smoking Cessation Success},
  journal = {Nicotine and Tobacco Research},
  year = {2023},
  doi = {10.1093/ntr/ntac268}
}
Kostenlos starten →